Personalis Inc
NASDAQ:PSNL
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.15
6.34
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PSNL stock under the Base Case scenario is 1.91 USD. Compared to the current market price of 3.47 USD, Personalis Inc is Overvalued by 45%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Personalis Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PSNL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Personalis Inc
Balance Sheet Decomposition
Personalis Inc
Current Assets | 170.3m |
Cash & Short-Term Investments | 143.7m |
Receivables | 13.5m |
Other Current Assets | 13.2m |
Non-Current Assets | 69.6m |
PP&E | 67m |
Other Non-Current Assets | 2.6m |
Current Liabilities | 36.4m |
Accounts Payable | 12.5m |
Accrued Liabilities | 17.5m |
Other Current Liabilities | 6.4m |
Non-Current Liabilities | 36.7m |
Long-Term Debt | 411k |
Other Non-Current Liabilities | 36.3m |
Earnings Waterfall
Personalis Inc
Revenue
|
87.5m
USD
|
Cost of Revenue
|
-60m
USD
|
Gross Profit
|
27.5m
USD
|
Operating Expenses
|
-97.6m
USD
|
Operating Income
|
-70.1m
USD
|
Other Expenses
|
-21.4m
USD
|
Net Income
|
-91.4m
USD
|
Free Cash Flow Analysis
Personalis Inc
USD | |
Free Cash Flow | USD |
PSNL Profitability Score
Profitability Due Diligence
Personalis Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
Score
Personalis Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
PSNL Solvency Score
Solvency Due Diligence
Personalis Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Score
Personalis Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PSNL Price Targets Summary
Personalis Inc
According to Wall Street analysts, the average 1-year price target for PSNL is 7.19 USD with a low forecast of 5.05 USD and a high forecast of 9.45 USD.
Dividends
Current shareholder yield for PSNL is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
PSNL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company is headquartered in Menlo Park, California and currently employs 325 full-time employees. The company went IPO on 2019-06-20. The firm is focused on the development of therapies by providing molecular data about each patient's cancer and immune response. The company provides sequencing and data analysis services to support the development of cancer therapies. Its NeXT Platform, which provides its biopharmaceutical customers with information on over 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover over 50 to 500 genes. Its NeXT Platform is designed to provide analysis of both a tumor and its immune microenvironment from a single limited tissue sample. Its platform covers the deoxyribonucleic acid sequence of all of the approximately 20,000 human genes. The company also reports on transcriptome of a tumor, which encompasses ribonucleic acid expression across human genes, allowing it to determine which of the genomic mutations might actually be driving tumor progression.
Contact
IPO
Employees
Officers
The intrinsic value of one PSNL stock under the Base Case scenario is 1.91 USD.
Compared to the current market price of 3.47 USD, Personalis Inc is Overvalued by 45%.